A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors

Xiaoli Wei(Anhui Medical University), Rui‐Hua Xu(Sun Yat-sen University), Feng Wang(Sun Yat-sen University), Miao‐Zhen Qiu(Sun Yat-sen University), Dongsheng Zhang(Sun Yat-sen University), Zhi‐Qiang Wang(Nanjing University of Chinese Medicine), Feng‐Hua Wang(Sun Yat-sen University), Chao Ren(Sun Yat-sen University), Hui Luo(Sun Yat-sen University), Benyan Zou(Sun Yat-sen University), Hongyun Zhao(Sun Yat-sen University), Yang Zhang(Dalian Medical University), Sheng Yao(BioReliance (United States))
Cancer Communications
June 26, 2020
10.1002/cac2.12068
Cited by 54

Related Papers

Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868
Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization
|Advanced Materials|2017|756
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657